Aspirin May Have an Impact on the Breast Cancer Cells


There are new studies that show that women that have some certain DNA characteristics in specific areas of the genome may actually live longer is they take aspirin.

The study was published online in CANCER, which is a peer-reviewed journal of the American Cancer Society. It talks about the potential of aspirin to prevent or even treat breast cancer in some women.

More often, it was unclear why some of the patients could benefit from an individual therapy, while others couldn’t. In some of the cases, genes played a role. However, in other cases, the chemical modifications of the DNA were crucial. We are talking about the epigenetic changes, and they include a certain process. The name of the process is DNA methylation.

Marilie Gammon, Ph.D. one of her colleagues, Tengteng Wang, Ph.D., MSPH, from the University of North Carolina at Chapel Hill have asked themselves if the DNA methylation could have an influence on the effects of the aspirin in those patients with breast cancer. The team has taken a look at the examined DNA methylation found in the tissue of the breast tumor. They have also taken a look at the DNA sites that have control over the expression of 13 breast cancer-related genes. They also studied the cells that circulate in the blood of the patients.

What is the aim of the study?

This study examines the effect of the DNA methylation when it comes to the use of aspirin and the mortality of women who are diagnosed with breast cancer.

In this study, 1266 women took part. They were diagnosed with breast cancer between 1996 and 1997. 476 of them died from random causes, and 202 died specifically of breast cancer by the end of 2014. Those women who took aspirin had lower chances to die from breast cancer. They were among those whose DNA was not methylated in the area that controlled the expression of the breast cancer-related BRCA1 gene.


Related Posts